Modulation of high-frequency oscillations associated with NMDA receptor hypofunction in the rodent nucleus accumbens by lamotrigine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 5, 2008, Pages 1312-1319

  Hunt, Mark J ^a,b,c   Garcia, Rene ^a,b,c   Large, Charles H ^a,b,c   Kasicki, Stefan ^a,b,c  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c GSK   (Italy)

Author keywords

frequency oscillations; Ketamine; Lamotrigine; LFP, local field potentials; LMA, locomotor activity; LTG, lamotrigine; NAc, nucleus accumbens; NMDA, N; Nucleus accumbens; Oscillations; Rats

Indexed keywords

KETAMINE; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INFUSION; DRUG MEGADOSE; HIGH FREQUENCY OSCILLATION; LOCOMOTION; LOW DRUG DOSE; MALE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PATHOPHYSIOLOGY; RAT; SCHIZOPHRENIA;

ALGORITHMS; ANALYSIS OF VARIANCE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; HIGH-FREQUENCY VENTILATION; KETAMINE; MALE; MEMBRANE POTENTIALS; MICROINJECTIONS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; SPECTRUM ANALYSIS; TIME FACTORS; TRIAZINES;

EID: 49849106428     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.04.009     Document Type: Article

References (47)

1. Abekawa T., Honda M., Ito K., and Koyama T. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats. Psychopharmacology (Berl) 169 (2003) 247-256
2. Adams B., and Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18 (1998) 5545-5554
3. Ahmad S., Fowler L.J., and Whitton P.S. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res 1029 (2004) 41-47
4. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., and Krystal J.H. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57 (2000) 270-276
5. Anand A., Charney D., Oren D., Berman R., Hu X., Cappiello A., and Krystal J. Potentiation of mood elevating effects of ketamine by lamotrigine: support for the mood elevating effect of inhibition of glutamatergic transmission (2000) XXII CINP Congress, P16.024
6. Bedard C., Kroger H., and Destexhe A. Model of low-pass filtering of local field potentials in brain tissue. Phys Rev E Stat Nonlin Soft Matter Phys 73 (2006) 051911
7. Berger T., and Luscher H.R. Associative somatodendritic interaction in layer V pyramidal neurons is not affected by the antiepileptic drug lamotrigine. Eur J Neurosci 20 (2004) 1688-1693
8. Brody S.A., Geyer M.A., and Large C.H. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169 (2003) 240-246
9. Cunningham M.O., and Jones R.S. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39 (2000) 2139-2146
10. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., and Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 65 (2008) 154-164
11. Fallon J.H., and Moore R.Y. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol 180 (1978) 545-580
12. Floresco S.B., Ghods-Sharifi S., Vexelman C., and Magyar O. Dissociable roles for the nucleus accumbens core and shell in regulating set shifting. J. Neurosci. 26 (2006) 2449-2457
13. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 31 (2000) 330-341
14. Grunze H., von W.J., Greene R.W., and Walden J. Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 38 (1998) 131-138
15. Homayoun H., Jackson M.E., and Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 93 (2005) 1989-2001
16. Hunt M.J., Kessal K., and Garcia R. Ketamine induces dopamine-dependent depression of evoked hippocampal activity in the nucleus accumbens in freely moving rats. J Neurosci 25 (2005) 524-531
17. Hunt M.J., and Kasicki S. Bilateral microinfusion of MK801 in the nucleus accumbens induces high-frequency oscillations (150 Hz) in freely moving rats. Soc Neurosci 498 (2007) 18P
18. Hunt M.J., Raynaud B., and Garcia R. Ketamine dose-dependently induces high-frequency oscillations in the nucleus accumbens in freely moving rats. Biol Psychiatry 60 (2006) 1206-1214
19. Idris N.F., Repeto P., Neill J.C., and Large C.H. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 179 (2005) 336-348
20. Imperato A., Honore T., and Jensen L.H. Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats. Brain Res 530 (1990) 223-228
21. Imre G., Fokkema D.S., Den Boer J.A., and Ter Horst G.J. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 69 3 (2006) 338-345
22. Jackson M.E., Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci U. S. A. 101 (2004) 8467-8472
23. Kessal K., Chessel A., Spennato G., and Garcia R. Ketamine and amphetamine both enhance synaptic transmission in the amygdala-nucleus accumbens pathway but with different time-courses. Synapse 57 (2005) 61-65
24. Kremer I., Vass A., Gorelik I., Bar G., Blanaru M., Javitt D.C., and Heresco-Levy U. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 56 (2004) 441-446
25. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
26. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., and Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169 (2003) 215-233
27. Lahti A.C., Koffel B., LaPorte D., and Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13 (1995) 9-19
28. Large C.H. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?. J Psychopharmacol 21 (2007) 283-301
29. Large C.H., Webster E.L., and Goff D.C. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 181 3 (2005) 415-436 Review
30. Leung L.S., and Yim C.Y. Rhythmic delta-frequency activities in the nucleus accumbens of anesthetized and freely moving rats. Can J Physiol Pharmacol 71 (1993) 311-320
31. Li X., Teneback C.C., Nahas Z., Kozel F.A., Large C., Cohn J., Bohning D.E., and George M.S. Interleaved transcranial magnetic stimulation/functional MRI confirms that lamotrigine inhibits cortical excitability in healthy young men. Neuropsychopharmacology 29 (2004) 1395-1407
32. Liu J., and Newsome W.T. Local field potential in cortical area MT: stimulus tuning and behavioral correlations. J Neurosci 26 (2006) 7779-7790
33. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., and Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMAArch Neurol Psychiatry 81 (1959) 363-369
34. Marcus M.M., Mathe J.M., Nomikos G.G., and Svensson T.H. Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens. Neuropharmacology 40 (2001) 482-490
35. Mogenson G.J., Jones D.L., and Yim C.Y. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 14 (1980) 69-97
36. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17 (1997) 2921-2927
37. Newman R., and Winans S.S. An experimental study of the ventral striatum of the golden hamster. I. Neuronal connections of the nucleus accumbens. J Comp Neurol 191 (1980) 167-192
38. O'Donnell P., and Grace A.A. Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. J Neurosci 15 (1995) 3622-3639
39. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52 (1995) 998-1007
40. Paxinos W, Watson C. The rat brain in stereotaxic coordinates, 1986 Ed 2. San Diego: Academic.
41. Razoux F., Garcia R., and Lena I. Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens. Neuropsychopharmacology 32 (2007) 719-727
42. Salamone J.D., Correa M., Mingote S.M., and Weber S.M. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol 5 (2005) 34-41
43. Shuaib A., Mahmood R.H., Wishart T., Kanthan R., Murabit M.A., Ijaz S., Miyashita H., and Howlett W. Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Res 702 (1995) 199-206
44. Tiihonen J., Hallikainen T., Ryynanen O.P., Repo-Tiihonen E., Kotilainen I., Eronen M., Toivonen P., Wahlbeck K., and Putkonen A. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54 (2003) 1241-1248
45. Williams H.J., Zamzow C.R., Robertson H., and Dursun S.M. Effects of clozapine plus lamotrigine on phencyclidine-induced hyperactivity. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 239-243
46. Xie X., and Hagan R.M. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 38 (1998) 119-130
47. Xie X., Lancaster B., Peakman T., and Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Pflugers Arch 430 (1995) 437-446